Ian Bolam

Ian Bolam currently serves as the Director of Regulatory Affairs International at Sobi - Swedish Orphan Biovitrum AB (publ) since January 2024. Prior to this role, Ian held the position of Regulatory Director for CNS/Pain at Abbott from March 2020 to November 2023. Previous experience includes serving as the Asia Pacific Regulatory Affairs Director at Celgene from August 2019 to March 2020, and as the Emerging Markets Regulatory Affairs Director at AstraZeneca from July 2015 to August 2019. Ian also worked as the Regulatory Affairs Director for Emerging Markets at Gilead Sciences from May 2008 to June 2015. Ian completed studies at The University of Sheffield.